Associate
Chris is involved in all aspects of patent litigation, including pre-litigation analysis; fact and expert discovery; claim construction; motions practice; trial; and handling day-to-day litigation activities. Through his opinion practice, he counsels clients on patent validity and potential product infringement. Chris's technical experience includes antibodies, gene editing technologies, transgenic animals, enzymology, chemical library screening, flow cytometry, and small molecule drugs.
Prior to law school, Chris performed research in the discovery and pre-clinical departments at a major pharmaceutical company. He received his doctorate in cell and molecular biology from the University of Pennsylvania Perelman School of Medicine, where he studied the role of deeply conserved non-coding genomic regions in the development of the vertebrate skeleton.
Chris dedicates time to pro bono representation. His efforts include drafting a successful motion to oppose summary judgment, resulting in a favorable settlement for a § 1983 prisoner claimant.
Genzyme Corporation et al. v. Novartis Gene Therapies, Inc. et al.
1:21-cv-01736, 1:23-cv-00554, D. Del., Judge Andrews
American Regent, Inc. v. Pharmacosmos Therapeutics Inc. et al.
3:20-cv-01350, D.N.J., Judges Goodman, Martinotti, Quraishi
PGR2020-00009, PTAB, Judges Tornquist, Franklin, Wisz
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.